# How many intentionally genomic DNA altered animals will be approved for consumption by the FDA on July 31, 2025? (QID: 38942)

- Type: numeric

- URL: https://www.metaculus.com/questions/38942/

- Classifier: health | strategic=False (score=0.00)

### SeenGuard

- enabled=True | lock_status=acquired

- run_filter: before=1 | skipped=0 | after=1

- debug_note=lock acquired

## Research (summary)

CALIBRATION GUIDANCE (auto-generated weekly):
BINARY CALIBRATION
- No resolved binary questions (with pre-resolution forecasts) yet.
- Advice: keep using base rates + small evidence-weighted updates; avoid big swings.

MULTIPLE-CHOICE CALIBRATION (Top-1)
- No resolved MCQ questions (with pre-resolution forecasts) yet.

NUMERIC CALIBRATION (PIT-lite + CRPS)
- No resolved numeric questions (with pre-resolution forecasts) yet.
- When numeric results exist, we’ll check p10/p50/p90 coverage and CRPS.

General takeaway: apply **small** nudges only where gaps are consistent with decent sample sizes (≥10).
— end calibration —

### Reference class & base rates
1.  **FDA Approvals of Intentionally Genomic DNA Altered (IGA) Animals for Food:** This is the most specific and relevant reference class. Since the FDA began regulating these animals, only one has ever been approved for human consumption: the AquAdvantage salmon (approved in 2015). The period of observation is roughly 25 years (since the technology became viable).
    *   **Base Rate:** 1 approval / 25 years = **0.04 approvals per year**.
    *   **Reasoning:** This rate reflects the immense technical, regulatory, and political friction involved. It captures the entire lifecycle from R&D to final approval.
    *   **Limitations:** With only one data point (n=1), this base rate is highly uncertain and may not reflect the current environment, especially with new technologies (CRISPR) and updated regulations.

2.  **FDA Center for Veterinary Medicine (CVM) New Animal Drug Approvals (NADA):** This is a broader class, including all novel drugs for animals, not just IGAs. The CVM approves dozens of new animal drugs each year.
    *   **Base Rate:** **~20-30 approvals per year** (based on CVM annual reports).
    *   **Reasoning:** This provides a sense of the CVM's maximum throughput for complex reviews.
    *   **Limitations:** This class is a poor proxy. IGAs for food face unique ethical, environmental, and public perception challenges that standard veterinary drugs do not, making their review process fundamentally slower and more contentious.

3.  **Global Approvals of IGA Animals for Food:** This class considers approvals in other jurisdictions (e.g., Canada, Brazil, Japan). Canada also approved the AquAdvantage salmon (2016). Japan approved two gene-edited fish (tiger puffer, red sea bream) in 2021. Brazil approved a gene-edited, disease-resistant sugarcane in 2018, but animal approvals are less common.
    *   **Base Rate:** Roughly **0.1-0.2 approvals per year globally** in recent years.
    *   **Reasoning:** Shows that regulatory progress is possible, especially for gene-edited (vs. transgenic) organisms in some countries.
    *   **Limitations:** The US FDA has historically been more cautious and subject to different political pressures and legal frameworks than regulators in other nations.

**Conclusion:** The most pertinent base rate is extremely low (0.04/year), suggesting new approvals are rare events.

### Recent developments (timeline bullets)
*   **2025-01-15** The commercial failure and production shutdown of AquAdvantage salmon is finalized. (↓) — This demonstrates that FDA approval does not guarantee market success, potentially reducing commercial urgency for other companies and increasing FDA caution about approving products with questionable viability.
*   **2024-05-01** FDA finalizes Guidance for Industry #187A, outlining a risk-based approach for IGAs. (↑) — This is a significant structural change. It creates a clearer, potentially faster pathway for low-risk alterations (e.g., single gene edits vs. transgenics), which could accelerate pending applications.
*   **2023-12-19** The FDA accepts for review Genus plc's application for PRRS-resistant pigs. (↑) — This is a major milestone. It officially starts the clock on the final, intensive phase of review for the most likely next candidate, making an approval within the timeframe plausible.
*   **2023-05-09** The UK passes legislation to streamline rules for gene-edited crops and animals. (↑) — While not in the US, this signals a broader trend in Western regulatory bodies toward a more permissive stance on gene editing (as distinct from GMOs), which could influence the FDA's posture.

### Mechanisms & drivers (causal levers)
1.  **FDA Regulatory Framework & Pace:** The single largest driver. The new risk-based GFI #187A could significantly shorten timelines compared to the 20-year saga of the transgenic salmon. However, the agency is inherently cautious and resource-constrained. (Size: Large)
2.  **Commercial Incentive & Viability:** The failure of AquAdvantage chills the market. Companies may be less willing to fund the final, expensive push for an approval if consumer acceptance is low. Conversely, a product with a clear and massive economic benefit (like PRRS-resistant pigs for the pork industry) retains a strong incentive. (Size: Moderate)
3.  **Public & Political Opposition:** Anti-GMO sentiment remains a powerful force that can trigger litigation and political intervention, slowing the FDA's process. The distinction between "gene-edited" and "transgenic" is not well understood by the public, so opposition may not differentiate. (Size: Moderate)
4.  **Candidate Pipeline Maturity:** The number of approvals is capped by the number of mature applications in the final stages of review. Currently, the PRRS-resistant pig from Genus is the most prominent candidate, with heat-tolerant cattle (Acceligen) also in development. The outcome depends heavily on the progress of these specific files. (Size: Large)
5.  **Potential for Regulatory Deregulation (Ambiguity Clause):** There is ongoing pressure from industry to move the regulation of some gene-edited animals from the FDA's drug framework to the USDA, which is perceived as more lenient. If this happens, the question resolves as Ambiguous. This is a binary, high-impact risk. (Size: Large)

### Differences vs. the base rate (what’s unusual now)
*   **New Regulatory Guidance:** The base rate was established under an old, cumbersome framework. The new GFI #187A (May 2024) explicitly creates a risk-based, streamlined path that did not exist for the AquAdvantage salmon.
*   **Technology Shift:** The salmon was a transgenic organism (genes from different species). The leading current candidates (pigs, cattle) primarily use gene editing (e.g., CRISPR) to make changes within a species' own gene pool. The FDA may view these as lower risk, fitting them into the new, faster pathway.
*   **The "First Mover" is Done:** The political and scientific battle to approve the *first* IGA animal for food has been fought. Subsequent approvals may face less friction, as precedent has been set.
*   **Post-Mortem of First Product:** Unlike the period leading up to the salmon's approval, we now have a clear data point on the commercial failure of an approved product. This adds a new layer of risk and consideration for both regulators and companies.

### Bayesian update sketch (for the statistician)
*   **Prior:** The base rate from the reference class of IGA approvals (n=1 over 25 years) suggests a prior heavily concentrated on 1 (the current number of approved animals). The probability of reaching 2 or more by the resolution date is extremely low. Let's model this as a Poisson process with a very low rate, λ≈0.04/year.
*   **Evidence mapping:**
    *   (↑ Large) **GFI #187A and Genus's application acceptance:** These two events are the strongest evidence for an update. They signal both a potentially faster process (mechanism) and a specific candidate entering that process (opportunity). This significantly increases the probability of one additional approval.
    *   (↓ Moderate) **Commercial failure of AquAdvantage:** This tempers the update, suggesting that even if regulatory hurdles are lowered, economic ones may cause companies or the FDA to de-prioritize the final push.
    *   (↑ Small) **Favorable international regulatory trends (e.g., UK):** Provides weak support for a more permissive environment in the US.
*   **Net effect:** The evidence strongly suggests an upward revision from the historical base rate. The prior, which saw an additional approval as nearly impossible, should be updated to view it as plausible, though still not the most likely outcome. The posterior should have significantly more mass on the outcome of **2** than the prior did, while **1** remains the modal outcome.

### Indicators to watch (leading signals; next weeks/months)
*   **UP indicators:**
    *   FDA announcement of a public comment period for a specific IGA animal file (e.g., Genus pigs).
    *   Press releases from Genus or Acceligen indicating they have reached the final stages of FDA review.
    *   Publication of the FDA's final environmental assessment or food safety determination for a candidate animal.
    *   Trade press articles quoting FDA officials on the successful implementation of the new risk-based guidance.
*   **DOWN indicators:**
    *   Lawsuits filed by consumer or environmental groups (e.g., Center for Food Safety) against the FDA regarding a specific IGA application.
    *   Announcements from Genus or other companies of delays in their expected regulatory timeline.
    *   Political rhetoric from Congress or the administration questioning the safety or oversight of IGA animals.
    *   Any movement on legislation to shift regulatory authority to the USDA (increases ambiguity risk).

### Caveats & pitfalls
*   **Ambiguity Risk:** The resolution criteria link to another question about regulatory oversight. If non-transgenic gene editing is deregulated by the FDA before July 2025, this question becomes Ambiguous. This is a major source of uncertainty.
*   **Definition of "variants of rDNA constructs":** The question counts "variants," not species. If a company gets approval for two different genetic edits in pigs, that could resolve as 2. However, the current paradigm is one complex application per product line (e.g., "the PRRS-resistant pig"). The most likely scenario is that one new approval = one new variant.
*   **Opacity of FDA Process:** The status of applications is confidential until the FDA makes a public announcement. We are forecasting based on public signals, but the crucial work is happening behind closed doors. A surprise approval or denial is possible.
*   **Hypothetical Sources:** The provided sources include dates in the future (Jan/Feb 2025). This brief treats their content as fact per the prompt's framing, but this is an artificiality of the scenario.

**Final Research Summary:** The historical base rate of one approval in 25 years suggests the number will remain at 1. However, the recent implementation of a new,

Market snapshot debug:
- Metaculus: no open binary results in response
- Manifold: no open binary results in response

### Sources
- Guidance for Industry #187A - Heritable Intentional Genomic Alterations in Animals: Risk-Based Approach - FDA (www.fda.gov) — https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-187a-heritable-intentional-genomic-alterations-animals-risk-based-approach
- Q&A on FDA's Approval of AquAdvantage Salmon (www.fda.gov) — https://www.fda.gov/animal-veterinary/aquadvantage-salmon/qa-fdas-approval-aquadvantage-salmon
- GMO Salmon Production Ends as Expert Groups Celebrate Victory (sustainablepulse.com) — https://sustainablepulse.com/2025/01/05/gmo-salmon-production-ends-as-expert-groups-celebrate-victory/
- Draft Guidance for Industry: Voluntary Labeling Indicating Whether Food Has or Has Not Been Derived From Genetically Engineered Atlantic Salmon (www.fda.gov) — https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-voluntary-labeling-indicating-whether-food-has-or-has-not-been-derived
- An HSUS Report: Welfare Issues with Genetic Engineering and Cloning of Farm Animals (www.humanesociety.org) — https://www.humanesociety.org/sites/default/files/docs/hsus-report-welfare-issues-genetic-engineering-cloning-farm-animals.pdf
- The rise and fall of genetically engineered salmon (www.nationalfisherman.com) — https://www.nationalfisherman.com/northeast/the-rise-and-fall-of-genetically-engineered-salmon
- AquAdvantage® Salmon's Journey to Market: Still Making History (www.aquabounty.com) — https://www.aquabounty.com/wp-content/uploads/2019/07/AquAdvantage-Salmon-Journey-to-Market-Hatchery-International-Nov-Dec-2018.pdf
- New labeling rule paves way for GM salmon to enter US market (www.seafoodsource.com) — https://www.seafoodsource.com/news/food-safety-health/new-labeling-rule-paves-way-for-gm-salmon-to-enter-us-market

### Research (debug)

- source=GoogleGrounding | llm=google/gemini-2.5-pro | cached=0 | n_raw=11 | n_kept=8 | cost=$0.029314

- query: format; metac_closes_in_period; info; post_id; question_id; variants of rDNA constructs in intentionally genomic DNA altered animals; animal drugs; HSUS Report; The AquAdvantage; AquAdvantage Salmon; 2006; 2019; 2025; 2018

### GTMC1 (debug)

- strategic_class=False | strategic_score=0.00 | source=llm

- gtmc1_active=False | qtype=numeric | t_ms=0

- actors_parsed=0

- exceedance_ge_50=None | coalition_rate=None | median=None | dispersion=None

### Ensemble (model outputs)

- OpenRouter-Default: ok=True t_ms=10346 P10=31.000, P50=2025.000, P90=1.000

- Claude-3.7-Sonnet (OR): ok=True t_ms=23375 P10=31.000, P50=2025.000, P90=1.000

- Gemini: ok=True t_ms=57346 P10=1.000, P50=25.000, P90=2015.000

- Grok: ok=False t_ms=272



### Per-model (raw + usage/cost)

#### OpenRouter-Default

- ok=True | t_ms=10346 | tokens: prompt=4432, completion=495, total=4927 | cost=$0.016030

```md

To forecast the number of intentionally genomic DNA altered animals approved for consumption by the FDA by July 31, 2025, we will follow the outlined Bayesian reasoning process.

1. **Base Rate (Prior) Selection**
   - The most relevant base rate is the historical approval rate of intentionally genomic DNA altered animals for food by the FDA, which is 1 approval over 25 years, or 0.04 approvals per year. This reflects the significant regulatory and technical challenges involved.

2. **Comparison to Base Case**
   - Similarities: The regulatory environment remains complex, and the FDA's cautious approach continues.
   - Differences: Recent regulatory changes (GFI #187A) and technological advancements (CRISPR) suggest a potentially faster approval process for certain gene-edited animals.

3. **Evidence Evaluation (Likelihoods)**
   - **GFI #187A and Genus's application acceptance**: These developments suggest a higher likelihood of approval, as they indicate a streamlined process and a viable candidate in the pipeline. This evidence increases the likelihood of at least one additional approval.
   - **Commercial failure of AquAdvantage salmon**: This suggests a lower likelihood of approval due to potential economic concerns, tempering the upward adjustment.
   - **Favorable international trends**: These provide moderate support for a more permissive regulatory stance in the US.

4. **Bayesian Updating (Posterior Distribution)**
   - Starting with a Poisson process with λ=0.04/year, the evidence (particularly GFI #187A and Genus's application) suggests a significant upward revision. The posterior distribution should reflect a higher probability of one additional approval, while still considering the base rate's constraints.

5. **Red Team Thinking**
   - Overconfidence risk: The forecast should account for the possibility of regulatory or political setbacks.
   - Alternative scenario: A scenario where no approvals occur due to unforeseen regulatory delays or market failures is plausible.
   - Adjustments: Consider the ambiguity risk if regulatory oversight changes, which could affect the resolution.

6. **Final Percentiles**
   - Based on the Bayesian update and red team considerations, the forecast percentiles are adjusted to reflect the increased likelihood of one additional approval, while maintaining a conservative stance due to historical constraints.

P10: 1  
P20: 1  
P40: 1  
P60: 1  
P80: 2  
P90: 2

```

#### Claude-3.7-Sonnet (OR)

- ok=True | t_ms=23375 | tokens: prompt=5046, completion=1150, total=6196 | cost=$0.032388

```md

# Forecast: FDA-Approved Genomic DNA Altered Animals for Consumption by July 31, 2025

## 1. Base Rate (Prior) Selection

The most relevant base rate is the historical FDA approval rate for intentionally genomic DNA altered (IGA) animals for food consumption:

- Only 1 approval (AquAdvantage salmon) in approximately 25 years of regulatory history
- This yields a base rate of 0.04 approvals per year
- The distribution is highly skewed, with the modal outcome being 1 (the current status quo)

This base rate suggests that by July 31, 2025 (about 8 months from now), the most likely outcome remains 1 approved animal. The prior probability of any additional approvals within this timeframe would be extremely low based purely on historical patterns.

## 2. Comparison to Base Case

**Similarities to base case:**
- FDA continues to regulate IGA animals as "animal drugs" under the same legal framework
- Public skepticism about genetically modified food animals persists
- The commercial failure of AquAdvantage salmon demonstrates market challenges even after approval

**Key differences from base case:**
- New FDA Guidance (GFI #187A) implemented in May 2024 creates a risk-based approach that could accelerate approvals for certain types of modifications
- Current applications focus on gene editing (CRISPR) rather than transgenic modifications, potentially qualifying for faster review
- The FDA has already accepted Genus plc's application for PRRS-resistant pigs for review (December 2023)
- The "first mover" barrier has been broken; subsequent approvals may face less scrutiny

## 3. Evidence Evaluation

**Evidence supporting higher numbers:**
- **FDA's acceptance of Genus plc's application** (December 2023): This is strong evidence (likelihood ratio ~3:1 favoring an increase) as it puts a specific candidate in the final review phase with sufficient time for approval before July 2025.
- **New FDA Guidance #187A** (May 2024): Provides a clearer, potentially faster pathway for approval (likelihood ratio ~2:1 favoring an increase).
- **International regulatory trends**: UK and Japan have approved gene-edited organisms more readily (weak evidence, likelihood ratio ~1.2:1).

**Evidence supporting lower numbers:**
- **Commercial failure of AquAdvantage salmon** (January 2025): Demonstrates market challenges even after approval, potentially reducing commercial urgency (likelihood ratio ~1.5:1 favoring status quo).
- **Historical regulatory caution**: The FDA has consistently applied stringent standards to novel food technologies (likelihood ratio ~2:1 favoring status quo).

## 4. Bayesian Updating

Starting with our prior centered heavily on 1 approved animal:
- Prior probabilities: P(0) = 0.01, P(1) = 0.94, P(2) = 0.04, P(3+) = 0.01

First update based on FDA's acceptance of Genus application and new guidance:
- Combined likelihood ratio ~6:1 favoring at least one new approval
- Interim posterior: P(0) = 0.01, P(1) = 0.75, P(2) = 0.20, P(3+) = 0.04

Second update incorporating commercial challenges and regulatory caution:
- Combined likelihood ratio ~3:1 favoring status quo
- Final posterior: P(0) = 0.01, P(1) = 0.85, P(2) = 0.12, P(3+) = 0.02

This suggests a significant but still modest probability (~14%) of at least one new approval by July 2025.

## 5. Red Team Thinking

**Potential blind spots:**
- **Regulatory timeline underestimation**: FDA reviews often take longer than expected. The Genus application might not complete review by July 2025 despite being accepted in December 2023.
- **Political intervention**: A change in administration or political pressure could accelerate or halt the approval process.
- **Ambiguity risk**: If regulatory authority shifts to USDA for non-transgenic modifications, the question resolves as ambiguous.

**Alternative forecast consideration:**
A more optimistic forecaster might argue that the FDA's acceptance of the Genus application, combined with the new guidance, signals a genuine shift in regulatory approach. They might assign P(2) = 0.30 or higher.

Rebuttal: While these changes are significant, the FDA's institutional caution and the complexity of these reviews make dramatic acceleration unlikely. The 8-month window until resolution is relatively short for completing a thorough review.

## 6. Final Percentiles

Given the discrete nature of this variable (whole numbers of approved animals) and the strong concentration of probability mass at 1, I'll construct a distribution that reflects this reality:

P10: 1
P20: 1
P40: 1
P60: 1
P80: 1
P90: 2

```

#### Gemini

- ok=True | t_ms=57346 | tokens: prompt=4794, completion=1760, total=11871 | cost=$0.023593

```md

Here is a probabilistic forecast following the specified Bayesian reasoning steps.

### 1. Base Rate (Prior) Selection
The most appropriate reference class is the history of FDA approvals for intentionally genomic DNA altered (IGA) animals for human consumption. The FDA's regulatory framework for these animals has been in place for decades.

*   **Reference Class:** FDA approvals of IGA animals for food.
*   **Data:** In the last ~25 years, only one such animal has been approved: the AquAdvantage salmon in 2015.
*   **Base Rate:** This gives a historical rate of 1 approval per 25 years, or **0.04 approvals per year**.
*   **Prior Distribution:** Based on this extremely low rate, the prior probability of seeing a new approval within the ~14-month forecast window is very low. Using a Poisson process with this rate, the probability of zero new approvals is ~95%, and the probability of one new approval is ~5%. My prior distribution is therefore heavily concentrated on the current total of **1**.

### 2. Comparison to Base Case
The current situation has key differences from the historical period that established the base rate.

*   **Similarities:** The FDA remains a cautious, risk-averse regulator. Public and political opposition to genetically modified organisms persists, creating potential for delays through litigation and political pressure. The process remains expensive and technically demanding for applicants.
*   **Differences:**
    1.  **New Regulatory Framework:** In May 2024, the FDA finalized Guidance for Industry #187A, establishing a new risk-based approach. This is a significant departure from the cumbersome "new animal drug" framework that the AquAdvantage salmon navigated and is intended to streamline approvals for lower-risk alterations.
    2.  **Technology Shift:** The leading candidates are now primarily gene-edited (e.g., using CRISPR) rather than transgenic (like the salmon). The FDA may view these as lower risk, making them eligible for the new, faster regulatory path.
    3.  **Mature Candidate Pipeline:** There is at least one well-advanced candidate. In December 2023, the FDA formally accepted for review an application from Genus plc for its PRRS-resistant pigs. This marks the start of the final, intensive review phase, making an approval within the forecast timeframe plausible.

### 3. Evidence Evaluation (Likelihoods)
I will evaluate the key evidence and its directional impact on the base rate.

*   **(↑ Strong Upward Pressure) New Guidance & Genus Application:** The combination of a new, faster regulatory pathway (GFI #187A) and a specific, commercially significant product (PRRS pigs) entering that pathway is the strongest piece of evidence. The resolution date of July 31, 2025, is ~19 months after the application's acceptance, a timeline that is plausible under a streamlined process. This evidence makes the outcome of a second approval (Total = 2) substantially more likely than the base rate suggests.
*   **(↓ Moderate Downward Pressure) Commercial Failure of AquAdvantage Salmon:** The first approved IGA animal was a commercial failure, with production ceasing. This demonstrates that regulatory approval does not guarantee market success. This could reduce the commercial urgency for other companies and may make the FDA more cautious about allocating resources to approve products with uncertain viability.
*   **(↓ Moderate Downward Pressure) Political & Bureaucratic Inertia:** The 2024 US election cycle and subsequent transition in early 2025 could introduce delays or policy shifts. Furthermore, large regulatory agencies like the FDA have significant institutional inertia, and the real-world speed of a "streamlined" process is yet to be proven.

### 4. Bayesian Updating (Posterior Distribution)
My prior was P(Total=1) ≈ 95% and P(Total=2) ≈ 5%. The evidence, particularly the existence of a mature candidate in a new, faster pipeline, warrants a significant update.

I will model the outcome by estimating the probability of the lead candidate's approval.
*   Let P(Genus pig approval by July 2025) be the key variable.
*   The base rate suggests this is very low (<5%).
*   The new guidance and application acceptance strongly suggest it is much higher.
*   The commercial failure and political risks temper this optimism.

Balancing these factors, I estimate a **20-25% probability** that the Genus pig is approved in time. The probability of another candidate (e.g., heat-tolerant cattle) being approved is much lower, perhaps 2-3%, as they appear to be further behind in the pipeline.

*   **Posterior Calculation:**
    *   P(0 new approvals) = P(no pig approval) × P(no other approval) ≈ (1 - 0.22) × (1 - 0.02) = 0.78 × 0.98 ≈ 0.76.
    *   P(1 new approval) ≈ P(pig approval) + P(other approval) ≈ 0.22 + 0.02 = 0.24. (Approximating as mutually exclusive for simplicity).
    *   P(2+ new approvals) is negligible (<1%).

This shifts my posterior distribution to approximately:
*   **P(Total = 1) ≈ 76%**
*   **P(Total = 2) ≈ 24%**
*   **P(Total ≥ 3) < 1%**

The mean of my posterior distribution is now approximately (1 * 0.76) + (2 * 0.24) = 1.24.

### 5. Red Team Thinking
My forecast is heavily dependent on the approval of one specific product: the PRRS-resistant pig.

*   **Argument for a Lower Forecast (closer to base rate):** I might be overestimating the speed and impact of the new FDA guidance. "Streamlined" for the FDA could still mean a multi-year process. The 19-month timeline from application acceptance to approval could be highly optimistic. Any unexpected scientific questions, or successful legal challenges from opposition groups, could easily push the timeline past July 2025. In this scenario, the probability of a new approval is closer to 5-10%, and the number almost certainly remains 1.
*   **Argument for a Higher Forecast:** The economic incentive for the PRRS pig is immense (saving the industry hundreds of millions annually), creating massive commercial and political will to accelerate approval. The new guidance may be genuinely effective, and the FDA may be eager to demonstrate its success with a high-profile candidate. In this world, the chance of approval could be as high as 40-50%.
*   **Conclusion:** My estimate of a ~24% chance of a second approval seems like a reasonable balance, acknowledging the strong positive signals while respecting the powerful historical base rate of regulatory slowness. The resulting distribution, with a 76% chance of the number remaining 1, is appropriately conservative.

### 6. Final Percentiles
Based on the posterior probability distribution of P(Total=1) ≈ 76% and P(Total=2) ≈ 24%, I derive the following percentiles. The distribution is discrete, so the percentiles will be concentrated on the integer values.

*   The cumulative probability of the outcome being 1 or less is 76%.
*   The cumulative probability of the outcome being 2 or less is 100%.

Therefore:
*   The 10th, 20th, 40th, and 60th percentiles all fall within the range where the outcome is 1.
*   The 80th and 90th percentiles fall within the range where the outcome is 2, as the cumulative probability at 1 (76%) is less than 80%.

P10: 1
P20: 1
P40: 1
P60: 1
P80: 2
P90: 2

```

#### Grok

- ok=False | t_ms=272 | tokens: prompt=0, completion=0, total=0 | cost=$0.000000

- error=HTTP 429: Your team 0101076a-72f1-4f25-a038-b346d74bbc8d has either used all available credits or reached its monthly spending limit. To continue making API requests, please purchase more credits or raise your spending limit.

### Aggregation (BMC)

- final_quantiles: P10=-989.7687861159009, P50=27.26434047119364, P90=1055.9035495863448

- bmc_summary={"mean": 32.77941068498927, "p10": -989.7687861159009, "p50": 27.26434047119364, "p90": 1055.9035495863448}